5-Azacitidine in aggressive myelodysplastic syndromes regulates chromatin structure at PU.1 gene and cell differentiation capacity

N Curik; P Burda; K Vargova; V Pospisil; M Belickova; P Vlckova; F Savvulidi; E Necas; H Hajkova; C Haskovec; J Cermak; M Krivjanska; M Trneny; P Laslo; A Jonasova; T Stopka

doi:10.1038/leu.2012.47

journal article Feb 20, 2012

5-Azacitidine in aggressive myelodysplastic syndromes regulates chromatin structure at PU.1 gene and cell differentiation capacity

N Curik P Burda K Vargova V Pospisil M Belickova P Vlckova F Savvulidi E Necas H Hajkova C Haskovec J Cermak M Krivjanska M Trneny P Laslo A Jonasova T Stopka

Leukemia Vol. 26 No. 8 pp. 1804-1811 · Springer Science and Business Media LLC

View at Publisher Save 10.1038/leu.2012.47

Topics

No keywords indexed for this article. Browse by subject →

References

44

[1]

Laslo P, Spooner CJ, Warmflash A, Lancki DW, Lee HJ, Sciammas R et al. Multilineage transcriptional priming and determination of alternate hematopoietic cell fates. Cell 2006; 126: 755–766. 10.1016/j.cell.2006.06.052

[2]

Dahl R, Simon MC . The importance of PU.1 concentration in hematopoietic lineage commitment and maturation. Blood Cells Mol Dis 2003; 31: 229–233. 10.1016/s1079-9796(03)00152-9

[3]

Stopka T, Amanatullah DF, Papetti M, Skoultchi AI . PU.1 inhibits the erythroid program by binding to GATA-1 on DNA and creating a repressive chromatin structure. EMBO J 2005; 24: 3712–3723. 10.1038/sj.emboj.7600834

[4]

Burda P, Curik N, Kokavec J, Basova P, Mikulenkova D, Skoultchi AI et al. PU.1 activation relieves GATA-1-mediated repression of Cebpa and Cbfb during leukemia differentiation. Mol Cancer Res 2009; 7: 1693–1703. 10.1158/1541-7786.mcr-09-0031

[5]

Ross IL, Yue X, Ostrowski MC, Hume DA . Interaction between PU.1 and another Ets family transcription factor promotes macrophage-specific Basal transcription initiation. J Biol Chem 1998; 273: 6662–6669. 10.1074/jbc.273.12.6662

[6]

Yamamoto H, Kihara-Negishi F, Yamada T, Hashimoto Y, Oikawa T . Physical and functional interactions between the transcription factor PU.1 and the coactivator CBP. Oncogene 1999; 18: 1495–1501. 10.1038/sj.onc.1202427

[7]

Hoogenkamp M, Krysinska H, Ingram R, Huang G, Barlow R, Clarke D et al. The Pu.1 locus is differentially regulated at the level of chromatin structure and noncoding transcription by alternate mechanisms at distinct developmental stages of hematopoiesis. Mol Cell Biol 2007; 27: 7425–7438. 10.1128/mcb.00905-07

[8]

Petrovick MS, Hiebert SW, Friedman AD, Hetherington CJ, Tenen DG, Zhang DE . Multiple functional domains of AML1: PU.1 and C/EBPalpha synergize with different regions of AML1. Mol Cell Biol 1998; 18: 3915–3925. 10.1128/mcb.18.7.3915

[9]

Wontakal SN, Guo X, Will B, Shi M, Raha D, Mahajan MC et al. A large gene network in immature erythroid cells is controlled by the myeloid and B cell transcriptional regulator PU.1. PLoS Genet 2011; 7: e1001392. 10.1371/journal.pgen.1001392

[10]

Okuno Y, Huang G, Rosenbauer F, Evans EK, Radomska HS, Iwasaki H et al. Potential autoregulation of transcription factor PU.1 by an upstream regulatory element. Mol Cell Biol 2005; 25: 2832–2845. 10.1128/mcb.25.7.2832-2845.2005

[11]

Chen H, Ray-Gallet D, Zhang P, Hetherington CJ, Gonzalez DA, Zhang DE et al. PU.1 (Spi-1) autoregulates its expression in myeloid cells. Oncogene 1995; 11: 1549–1560.

[12]

Rosenbauer F, Wagner K, Kutok JL, Iwasaki H, Le Beau MM, Okuno Y et al. Acute myeloid leukemia induced by graded reduction of a lineage-specific transcription factor, PU.1. Nat Genet 2004; 36: 624–630. 10.1038/ng1361

[13]

Steidl U, Steidl C, Ebralidze A, Chapuy B, Han HJ, Will B et al. A distal single nucleotide polymorphism alters long-range regulation of the PU.1 gene in acute myeloid leukemia. J Clin Invest 2007; 117: 2611–2620. 10.1172/jci30525

[14]

Leddin M, Perrod C, Hoogenkamp M, Ghani S, Assi S, Heinz S et al. Two distinct auto-regulatory loops operate at the PU.1 locus in B cells and myeloid cells. Blood 2011; 117: 2827–2838. 10.1182/blood-2010-08-302976

[15]

Cook WD, McCaw BJ, Herring C, John DL, Foote SJ, Nutt SL et al. PU.1 is a suppressor of myeloid leukemia, inactivated in mice by gene deletion and mutation of its DNA binding domain. Blood 2004; 104: 3437–3444. 10.1182/blood-2004-06-2234

[16]

Mueller BU, Pabst T, Osato M, Asou N, Johansen LM, Minden MD et al. Heterozygous PU.1 mutations are associated with acute myeloid leukemia. Blood 2002; 100: 998–1007. 10.1182/blood.v100.3.998

[17]

Lamandin C, Sagot C, Roumier C, Lepelley P, De Botton S, Cosson A et al. Are PU.1 mutations frequent genetic events in acute myeloid leukemia (AML)? Blood 2002; 100: 4680–4681. 10.1182/blood-2002-08-2563

[18]

Vegesna V, Takeuchi S, Hofmann WK, Ikezoe T, Tavor S, Krug U et al. C/EBP-beta, C/EBP-delta, PU.1, AML1 genes: mutational analysis in 381 samples of hematopoietic and solid malignancies. Leuk Res 2002; 26: 451–457. 10.1016/s0145-2126(01)00150-3

[19]

Rekhtman N, Radparvar F, Evans T, Skoultchi AI . Direct interaction of hematopoietic transcription factors PU.1 and GATA-1: functional antagonism in erythroid cells. Genes Dev 1999; 13: 1398–1411. 10.1101/gad.13.11.1398

[20]

Nerlov C, Querfurth E, Kulessa H, Graf T . GATA-1 interacts with the myeloid PU.1 transcription factor and represses PU.1-dependent transcription. Blood 2000; 95: 2543–2551. 10.1182/blood.v95.8.2543

[21]

Zhang P, Zhang X, Iwama A, Yu C, Smith KA, Mueller BU et al. PU.1 inhibits GATA-1 function and erythroid differentiation by blocking GATA-1 DNA binding. Blood 2000; 96: 2641–2648. 10.1182/blood.v96.8.2641

[22]

Moreau-Gachelin F, Tavitian A, Tambourin P . Spi-1 is a putative oncogene in virally induced murine erythroleukaemias. Nature 1988; 331: 277–280. 10.1038/331277a0

[23]

O’Connell RM, Rao DS, Chaudhuri AA, Boldin MP, Taganov KD, Nicoll J et al. Sustained expression of microRNA-155 in hematopoietic stem cells causes a myeloproliferative disorder. J Exp Med 2008; 205: 585–594. 10.1084/jem.20072108

[24]

Durual S, Rideau A, Ruault-Jungblut S, Cossali D, Beris P, Piguet V et al. Lentiviral PU.1 overexpression restores differentiation in myeloid leukemic blasts. Leukemia 2007; 21: 1050–1059. 10.1038/sj.leu.2404645

[25]

Tatetsu H, Ueno S, Hata H, Yamada Y, Takeya M, Mitsuya H et al. Down-regulation of PU.1 by methylation of distal regulatory elements and the promoter is required for myeloma cell growth. Cancer Res 2007; 67: 5328–5336. 10.1158/0008-5472.can-06-4265

[26]

Mueller BU, Pabst T, Fos J, Petkovic V, Fey MF, Asou N et al. ATRA resolves the differentiation block in t(15;17) acute myeloid leukemia by restoring PU.1 expression. Blood 2006; 107: 3330–3338. 10.1182/blood-2005-07-3068

[27]

Gu ZM, Liu CX, Wu SF, Zhao M, Xu HZ, Liu W et al. PU.1 directly regulates retinoic acid-induced expression of RIG-G in leukemia cells. FEBS Lett 2010; 585: 375–380. 10.1016/j.febslet.2010.12.021

[28]

Silverman LR, McKenzie DR, Peterson BL, Holland JF, Backstrom JT, Beach CL et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol 2006; 24: 3895–3903. 10.1200/jco.2005.05.4346

[29]

Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009; 10: 223–232. 10.1016/s1470-2045(09)70003-8

[30]

Randomized Controlled Trial of Azacitidine in Patients With the Myelodysplastic Syndrome: A Study of the Cancer and Leukemia Group B

Lewis R. Silverman, Erin P. Demakos, Bercedis L. Peterson et al.

Journal of Clinical Oncology 2002 10.1200/jco.2002.04.117

[31]

Fenaux P, Gattermann N, Seymour JF, Hellstrom-Lindberg E, Mufti GJ, Duehrsen U et al. Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-C. Br J Haematol 2010; 149: 244–249. 10.1111/j.1365-2141.2010.08082.x

[32]

Fenaux P, Bowen D, Gattermann N, Hellstrom-Lindberg E, Hofmann WK, Pfeilstocker M et al. Practical use of azacitidine in higher-risk myelodysplastic syndromes: an expert panel opinion. Leuk Res 2010; 34: 1410–1416. 10.1016/j.leukres.2010.05.021

[33]

Quintas-Cardama A, Santos FP, Garcia-Manero G . Therapy with azanucleosides for myelodysplastic syndromes. Nat Rev Clin Oncol 2010; 7: 433–444. 10.1038/nrclinonc.2010.87

[34]

Komashko VM, Farnham PJ . 5-Azacytidine treatment reorganizes genomic histone modification patterns. Epigenetics 2010; 5: 229–240. 10.4161/epi.5.3.11409

[35]

Vire E, Brenner C, Deplus R, Blanchon L, Fraga M, Didelot C et al. The Polycomb group protein EZH2 directly controls DNA methylation. Nature 2006; 439: 871–874. 10.1038/nature04431

[36]

Hernandez-Munoz I, Taghavi P, Kuijl C, Neefjes J, van Lohuizen M . Association of BMI1 with polycomb bodies is dynamic and requires PRC2/EZH2 and the maintenance DNA methyltransferase DNMT1. Mol Cell Biol 2005; 25: 11047–11058. 10.1128/mcb.25.24.11047-11058.2005

[37]

Li H, Rauch T, Chen ZX, Szabo PE, Riggs AD, Pfeifer GP . The histone methyltransferase SETDB1 and the DNA methyltransferase DNMT3A interact directly and localize to promoters silenced in cancer cells. J Biol Chem 2006; 281: 19489–19500. 10.1074/jbc.m513249200

[38]

Smallwood A, Esteve PO, Pradhan S, Carey M . Functional cooperation between HP1 and DNMT1 mediates gene silencing. Genes Dev 2007; 21: 1169–1178. 10.1101/gad.1536807

[39]

Jiemjit A, Fandy TE, Carraway H, Bailey KA, Baylin S, Herman JG et al. p21(WAF1/CIP1) induction by 5-azacytosine nucleosides requires DNA damage. Oncogene 2008; 27: 3615–3623. 10.1038/sj.onc.1211018

[40]

Hu Z, Negrotto S, Gu X, Mahfouz R, Ng KP, Ebrahem Q et al. Decitabine maintains hematopoietic precursor self-renewal by preventing repression of stem cell genes by a differentiation-inducing stimulus. Mol Cancer Ther 2010; 9: 1536–1543. 10.1158/1535-7163.mct-10-0191

[41]

Drexler HG, Dirks WG, Macleod RA . Many are called MDS cell lines: one is chosen. Leuk Res 2009; 33: 1011–1016. 10.1016/j.leukres.2009.03.005

[42]

Si J, Boumber YA, Shu J, Qin T, Ahmed S, He R et al. Chromatin remodeling is required for gene reactivation after decitabine-mediated DNA hypomethylation. Cancer Res 2010; 70: 6968–6977. 10.1158/0008-5472.can-09-4474

[43]

Dotti G, Stella CC, Mangoni L, Cottafavi L, Caramatti C, Almici C et al. Granulocyte colony-stimulating factor (G-CSF) prevents dose-limiting neutropenia in lymphoma patients receiving standard dose chemotherapy. Haematologica 1995; 80: 142–145.

[44]

Estey E, Thall P, Andreeff M, Beran M, Kantarjian H, O’Brien S et al. Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor. J Clin Oncol 1994; 12: 671–678. 10.1200/jco.1994.12.4.671

Metrics

38

Citations

44

References

Details

Published: Feb 20, 2012
Vol/Issue: 26(8)
Pages: 1804-1811
License: View

Authors

Cite This Article

N Curik, P Burda, K Vargova, et al. (2012). 5-Azacitidine in aggressive myelodysplastic syndromes regulates chromatin structure at PU.1 gene and cell differentiation capacity. Leukemia, 26(8), 1804-1811. https://doi.org/10.1038/leu.2012.47

5-Azacitidine in aggressive myelodysplastic syndromes regulates chromatin structure at PU.1 gene and cell differentiation capacity

You May Also Like